Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK2336805 and TMC435 in Healthy Japanese Subjects
NCT02018536Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2013
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK2336805 in hepatitis C (HCV) (7 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum observed plasma concentration at Day 10, Area under the plasma concentration-time curve at Day 10 and 1 more. Started Oct 2013; status: completed.
02
Drugs
GSK2336805
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02018536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02018536.